Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.23B
Market cap12.23B
Price-Earnings ratio
-36.00
Price-Earnings ratio-36.00
Dividend yield
Dividend yield
Average volume
1.58M
Average volume1.58M
High today
$75.93
High today$75.93
Low today
$73.32
Low today$73.32
Open price
$75.89
Open price$75.89
Volume
1.02M
Volume1.02M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$32.00
52 Week low$32.00

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $74.03, giving the company a market capitalization of 12.23B. It carries a P/E multiple of -36.00.

As of 2026-05-15, Ionis Pharmaceuticals(IONS) stock has fluctuated between $73.32 and $75.93. The current price stands at $74.03, placing the stock +1.0% above today's low and -2.5% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 1.02M, against a daily average of 1.58M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $32.00 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $32.00 at its lowest and $86.74 at its peak.

IONS News

TipRanks 9h
Ionis Pharmaceuticals: Buy Rating Reaffirmed as Alzheimer’s Program Advances and Price Target Raised to $111 from $100

In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $111.00....

TipRanks 10h
Pelacarsen Phase 3 HORIZON Trial Seen as Key Catalyst Supporting Ionis Buy Rating and Unchanged $105 Price Target

Analyst Joseph Stringer of Needham maintained a Buy rating on Ionis Pharmaceuticals, retaining the price target of $105.00. Claim 55% Off TipRanks Unlock hedge...

TipRanks 1d
Ionis announces Biogen’s CELIA study did not meet primary endpoint

Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an...

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.